Meeting
2022 ASCO Annual Meeting
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
Authors
Qiang Zhang
Northwestern University, Department of Medicine, Division of Hematology/Oncology, CTC Core Facility, Lurie Cancer Center, Chicago, IL
Qiang Zhang , Weijun Qin , Paolo D’Amico , Jianhua Jiao , Andrew A. Davis , Lorenzo Gerratana , Jeannine Donahue , Carolina Reduzzi , Marwa Manai , Saya Jacob , Youbin Zhang , Lisa E. Flaum , Amir Behdad , Massimo Cristofanilli , Leonidas C. Platanias , Ami N. Shah , William John Gradishar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1057)
DOI
10.1200/JCO.2022.40.16_suppl.1057
Abstract #
1057
Poster Bd #
435
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor.
First Author: Hee-Chul Shin
Poster
2012 ASCO Annual Meeting
Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy.
First Author: Farideh Z. Bischoff
Poster
2011 Breast Cancer Symposium
Factors associated with mortality after breast cancer metastasis.
First Author: S. Y. Jung
Poster
2017 ASCO Annual Meeting
Overall survival (OS) of men and women with breast cancer according to tumor subtype: A population-based study.
First Author: Julieta Leone